Results 251 to 260 of about 151,608 (341)

Clinical Trial: Dose‐Finding Study of Linaprazan Glurate, A Novel Potassium‐Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Linaprazan glurate achieved a 4‐week healing rate of 71.1% in the intention‐to‐treat (ITT) analysis and 80.9% in the per protocol set (PPS) analysis. In comparison, lansoprazole achieved healing rates of 60.6% (ITT) and 59.1% (PPS). ABSTRACT Background Linaprazan glurate, a potassium‐competitive acid blocker, is in development for the treatment of ...
Prateek Sharma   +9 more
wiley   +1 more source

Evaluating the impact of general practice pharmacist‐led person‐centred medicines reviews on medicines appropriateness and patient‐reported outcome measures

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to investigate the impact of pharmacist‐led person‐centred medicines reviews in general practices on medicines appropriateness, polypharmacy indicators (high‐risk prescribing markers), and patient‐reported outcome measures (PROMs).
Clare Kinahan   +9 more
wiley   +1 more source

Diagnostic testing and treatment in Japanese patients with a diagnosis code for chronic inflammatory demyelinating polyradiculoneuropathy: A claims database analysis

open access: yesClinical and Experimental Neuroimmunology, EarlyView.
Abstract Objectives Reports of real‐world data concerning chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are limited in Japan. This study aimed to investigate the diagnostic testing and treatment performed in patients diagnosed with CIDP in Japan. Methods Using a Japanese commercial medical information database, we analyzed diagnostic
Motoi Kuwahara   +5 more
wiley   +1 more source

Contact Urticaria and Related Conditions: Clinical Review

open access: yesContact Dermatitis, EarlyView.
ABSTRACT Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non‐immunologic (NI‐CoU) and immunologic (I‐CoU) types, with I‐CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the
Mojca Bizjak   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy